Revenue and net profit both grew over 5% year-over-year, driven by strong sales of injectable products and robust R&D investment. The company maintained high gross margins, expanded its product portfolio, and announced a significant cash dividend, while continuing to invest in innovation and digital transformation.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.